7月10日晚，利民股份（002734）（002734.SZ）发布公告称，公司控股股东、实际控制人李明计划在公 告之日起15个交易日后的90个自然日内，通过大宗交易及集中竞价方式减持公司股份不超过1310.49万 股，占公司总股本的3%，减持原因为融资还款需求。 2024年利民股份业绩迎来增长。公司2024年实现营业总收入42.37亿元，同比增长0.32%；归母净利润 8135.76万元，同比增长31.11%。今年一季度，公司进一步扭亏为盈：实现营业收入12.11亿元，同比增 长22.28%；归母净利润1.08亿元，上年同期净亏损849.17万元。 对于今年一季度公司的业绩表现，利民股份在5月7日举行业绩说明会上表示，主要原因为公司主导产品 需求旺盛，代森锰锌、百菌清等高性价比杀菌剂因巴西大豆锈病爆发及渠道低库存等影响，价格持续走 高，产品供不应求；阿维、甲维盐系列产品受氯虫苯甲酰胺抗性增强带动复配需求增加，以及厂家关 停、转产导致供应紧张，价格持续上行；集采及供应商管理不断优化，降低了原材料采购成本，通过优 化资源配置，不断提升运营效率，降低费用支出等。 业绩表现亮眼的同时，利民股份也持续上涨。截至7月11日 ...

周期底部，看好涨价和科技材料 - 2025 年化工中期策略 20260626 摘要 基础化工板块估值处于历史低位，PB 分位数低于 10%时配置性价比凸 显，但需关注不同品类周期位置带来的阶段性机会，建议标配有边际变 化的子行业，如荣耀和甜味剂。 市场对油价关注点在于 OPEC 增产和美国页岩油供给。OPEC 增产策略 因沙特和俄罗斯财政赤字难以长期维持，美国页岩油储量理论寿命下降， 未来产量可能见顶。 基础化工板块整体承压，但新增产能、库存、需求及估值或已见底。固 定资产指数经历多轮扩张周期，库存处于底部，需求平稳但有差异，大 部分子行业 PB 分位数较低。 2025 年上半年看好白金烯和甲维盐，受益于供需双好，无新增产能且 需求增长。同时关注草甘膦，中国占全球产能 61%，国内竞争格局良好。 甜味剂市场供需格局较好，化工行业协同可能发生边际变化。以安赛蜜 为例，供给格局集中，市场具有稳定性和潜力。 Q&A 2025 年中期基础化工板块的投资策略是什么？ 2025 年中期基础化工板块的投资策略可以总结为"新趋势持续加强"，主要 分为三个部分：边际变化、贸易通和业绩兑现。当前基础化工板块处于赔率较 高但胜率不 ...

| | 代码 | 名称 | 治福 | 现价 涨停分析 | 几天几板+ | 换手 | | --- | --- | --- | --- | --- | --- | --- | | 1 | 002826 | 易明医药 | +9.99% | 21.57 控制权变更+糖尿病自仿药 6连板 | | 5.04% | | 2 | 002878 | 兀库雅图 | +9.98% | 20.60 数字文创资产+IP文创+Web. 9天5板 | | 29.65% | | 3 | 002940 | 司利康 | +9.98% | 26.11 NHKC-1+创新药+仿制药+宠 7天5板 | | 29.07% | | प | 600232 | 金鹰股份 | +10.00% | 8.47 注塑机+纺织机械+锂电池+起 4连板 | | 31.80% | | e | 003040 | 楚天龙 | +10.03% | 19.20 数字人民币+跨境支付 | 4大 3板 | 28.22% | | 6 | 002181 | 粤传媒 | +9.95% | 8.07 Al营销+体育产业+报业传媒 3连板 | | 8.84% | | 7 | 603332 | ...

| 上榜热股 | 实时涨跌幅 | 买/卖家数 | | | --- | --- | --- | --- | | 利民股份 002734.SZ | +10.02% | 3/2 | +1 | | 昂利康 002940.SZ | +9.98% | 4/2 | +1 | | 3日 | | | | 利民股份 龙虎榜机构热股 今天机构龙虎榜上榜30只个股，净买入9只，净卖出21只。当日机构买入最多的个股前三位是：利民股份（1.93亿）、昂利康（3日1.7亿）、澳洋健康（1356 万）。 龙虎榜显示，5家机构净买入1.93亿。 国联民生证券表示，公司同步推进"AI+农药"与合成生物学双轮驱动战略，通过德彦智创平台整合AI算法与生物合成技术，叠加与全球农化巨头的商业化协 同，有望进一步强化其在绿色农药创制领域的先发优势。短期来看，受益于阿维菌素、甲维盐、百菌清、代森锰锌等主要产品价格上涨，公司盈利能力有望 持续修复。 龙虎榜知名游资 个股龙虎榜 二、盲盒、IP经济 催化方面，泡泡玛特6月11日收涨4.25%，再创历史新高。 青木科技 个股龙虎榜 一、汽车零部件 近日，中国一汽、东风汽车、赛力斯集团、广州汽车集团、吉利汽车集团、 ...

氯虫苯甲酰胺是全球第一大杀虫剂，全球年销售额超20亿美元。2022年8月其在中国化合物专利到期后，市场价格持续下 降，2024年原药价格全年累计跌幅达34.38%。2025年以来，受中间体及开工率影响，有效产能释放偏低，价格触底反弹， 5月25日涨至22.8万元/吨，涨幅8.57%。目前国内在建/规划的氯虫苯甲酰胺原药产能超10万吨/年，但受中间体K胺供应及原 药价格下行影响，前期规划产能建设进度放缓。 市场迅速作出反应，6月9日农药板块延续强势，长青股份2连板、广康生化"20CM"涨停创历史新高，联化科技涨停，ST红 太阳等多股跟涨。分析人士普遍认为，氯虫苯甲酰胺价格有望出现阶段性上涨行情。后续涉及硝化、氯化等高危化工反应 的项目审批和生产监管将进一步趋严，化工行业头部企业可凭借现有产品稳定生产受益。 因市场供应格局变化，投资者对相关企业氯虫苯甲酰胺业务关注度提升，多家上市公司积极回应。联化科技称以CDMO模 式提供高级中间体，不直接生产该产品，合作模式为定制加工，相关事项对公司整体影响有限；辉隆股份年产2000吨氯虫 苯甲酰胺原药及中间体项目分期稳步推进；利尔化学5000吨/年生产装置有序建设中；长青股份 ...

Core Viewpoint - The price of 97% chlorantraniliprole has been adjusted to 300,000 yuan/ton due to limited supply of upstream raw materials, marking an increase of over 40% compared to the low point of 210,000 yuan/ton last year. This price adjustment is expected to lead to a phase of price increase in the market for chlorantraniliprole [1][2]. Industry Summary - Chlorantraniliprole has a global annual sales exceeding $2 billion, making it the largest insecticide worldwide. It was discovered by the former DuPont company in 2000 and was first launched in 2008. The expiration of its compound patent in China on August 13, 2022, significantly changed the market landscape [2]. - Following the patent expiration, the market price of chlorantraniliprole continued to decline, with a cumulative drop of 34.38% from 320,000 yuan/ton at the beginning of 2024 to 210,000 yuan/ton by the end of the year. However, since 2025, prices have rebounded from 210,000 yuan/ton to 228,000 yuan/ton as of May 25, 2025, reflecting an increase of 8.57% [2]. - Currently, over 100,000 tons/year of chlorantraniliprole production capacity is under construction or planned in China. However, actual progress has been hindered by the supply of intermediates and the continuous decline in raw material prices [2]. Company Responses - Lianhua Technology announced that it provides advanced intermediates for chlorantraniliprole through a CDMO business model and does not directly produce chlorantraniliprole. The company has a long-term partnership with its client and has not received any notifications regarding increased demand for related products [3]. - Huayong Co. stated that it has an annual production capacity of 2,000 tons of chlorantraniliprole and intermediates, with steady progress in project construction [3]. - Lier Chemical expressed optimism about the market prospects for chlorantraniliprole and is currently constructing a production facility with a capacity of 5,000 tons/year [3]. - Liming Co. indicated that its products cover various categories of insecticides, and if chlorantraniliprole supply tightens, it may boost the demand for its widely used insecticides, such as abamectin and methomyl, which have overlapping efficacy with chlorantraniliprole [4]. - Industry insiders noted that if the price of chlorantraniliprole rises sharply in the short term, downstream users may opt for alternative insecticides, increasing the demand for substitutes [4].

近日，红太阳的一则涨价函再度点燃了行业的热情。 根据涨价函，因上游原材料供应受限、主要原材料货紧价扬，导致公司氯虫苯甲酰胺成本急剧上升，经研究决定，97%氯虫苯甲酰胺产品价格调整至30万 元/吨，且限量供应。 受此影响，今日农药板块逆势拉升，苏利股份、先达股份、长青股份先后涨停，联化科技、利尔化学、ST红太阳、中旗股份等跟涨。 | | 名称 | 涨幅+ | 涨跌 | 现价 | | --- | --- | --- | --- | --- | | 1 | 苏利股份 | +9.98% | +1.73 | 19.06 | | 2 | 先达股份 | +9.98% | +0.98 | 10.80 | | 3 | 长青股份 | +9.95% | +0.56 | 6.19 | | 4 | 联化科技 | +6.68% | +0.86 | 12.83 | | 5 | 利尔化学 | +6.36% | +0.71 | 12.03 | | 6 | 广康生化 | +6.29% | +2.88 | 47.70 | | 7 | ST红太阳 | +4.62% | +0.36 | 8.15 | | 8 | 中旗股份 | +4.60% | +0. ...

每经记者｜赵李南 每经编辑｜张海妮 6月5日，ST红太阳（SZ000525，股价7.79元，市值101.12亿元，以下简称红太阳）股价涨停。红太阳当日上午在其官方微信公众号上发布调价函，将97%氯 虫苯甲酰胺产品价格调整至30万元/吨，并且限量供应。 《每日经济新闻》记者注意到，氯虫苯甲酰胺作为全球第一大杀虫剂，是妥妥的"杀虫剂一哥"。 记者致电红太阳证券部，工作人员告诉记者，目前受上游原材料短缺影响，氯虫苯甲酰胺的供给偏紧。 除ST红太阳外，海利尔（SH603639）、善水科技（SZ301190）、长青股份（SZ002391）、广信股份（SH603599）等相关概念股的股价也有不同程度的上 涨。 多只概念股上涨 6月5日上午，红太阳在其官方微信公众号发布《关于红太阳股份97%氯虫苯甲酰胺产品调价的函》。 红太阳称："由于上游原材料供应受限，主要原材料货紧价扬，导致我公司氯虫苯甲酰胺成本急剧上升，受此影响，经公司研究决定，97%氯虫苯甲酰胺产 品价格调整至30万元/吨，限量供应。" 图片来源：红太阳微信公众号截图 6月5日，ST红太阳股价开盘后快速上涨，并以涨停价报收，涨幅约为5%。 除ST红太阳外，6月5日 ...

据悉，友道化学成立于2019年8月，是豪迈集团股份有限公司控股子公司，位于山东省潍坊市高密仁和 化工园区。该公司聚焦高效低毒类农药及其专用中间体领域，主要产品包括氯虫苯甲酰胺原药及其中间 体，目前氯虫苯甲酰胺原药合计产能达1.1万吨/年，成为全球产能最大、产业链最完整的氯虫苯甲酰胺 原药生产企业。 氯虫苯甲酰胺是一种高效广谱低毒的杀虫剂，广泛用于水稻、大豆、棉花、果蔬等农作物。2008年上市 后，该产品已成为全球销售额最大的杀虫剂产品。目前，国内氯虫苯甲酰胺原药实际产量主要由河北诚 信、友道化学、红太阳、利尔化学、富美实中国工厂、内蒙古中高等企业所占据，其他厂家虽然也有在 建项目，但多处于未投产阶段。据不完全统计，目前全国氯虫苯甲酰胺原药产能约20万吨/年(含投产、 在建、申报项目)，而去年全年实际产量不足6000吨(不含富美实中国区工厂原药产量)，全球氯虫苯甲酰 胺原药需求量约为1万吨/年。长期来看，全球氯虫苯甲酰胺产能已远超需求。 今年以来，叠加春耕旺季需求，氯虫苯甲酰胺原药价格已从年初的21万元(吨价，下同)反弹至23万元。 受此事件影响，截至5月28日，氯虫苯甲酰胺原药价格已涨至25万元，涨幅约10% ...

Vitamin Sector - The vitamin sector is expected to benefit from price increases in 2024 and Q1 2025, with revenue projected to grow by 22.5% and net profit by 162.6% year-on-year in 2024 [1] - In Q1 2025, revenue and net profit are anticipated to continue their upward trend, with increases of 10.8% and 110.3% year-on-year, respectively [1] - The demand for feed-grade vitamins remains rigid, and certain concentrated supply structures are expected to support price increases for products like Vitamin E, D3, and folic acid [1] Fine Chemicals Sector - The fine chemicals sector is projected to outperform the basic chemicals sector in 2024 and Q1 2025, with a decline of only 4.2% in 2024 compared to a 5.1% drop in basic chemicals [2] - By the end of Q1 2025, the fine chemicals index is expected to rebound to 6905.55 points, reflecting an 8.5% increase year-to-date, surpassing basic chemicals by 2.4 percentage points [2] - The fine chemicals industry benefits from relatively inelastic downstream demand and high production barriers, making it more resilient during downturns and more elastic during recoveries [2] Amino Acids Sector - The amino acids sector is forecasted to see revenue growth of 8.9% and net profit growth of 55.0% in 2024, driven by recovering demand and lower raw material costs [3] - In Q1 2025, the sector is expected to continue benefiting from lower corn prices and increased export demand, with revenue and net profit projected to rise by 9.0% and 74.6% year-on-year, respectively [3] - Notably, methionine prices are anticipated to rise due to low channel inventory and market expectations, presenting potential opportunities for price increases [3] Pesticides Sector - The pesticides sector is showing signs of a cyclical rebound from 2024 to Q1 2025, despite an overall oversupply in 2024 leading to a revenue decline of 2.3% and a net profit drop of 73% [4] - In Q1 2025, certain pesticide products are expected to experience rapid price increases due to temporary supply-demand imbalances, resulting in a revenue increase of 4.5% and a net profit increase of 57.2% year-on-year [4] - Future price increases may be driven by strong demand for specific crops and supply constraints due to uncontrollable factors [4] Sweeteners Sector - The sweeteners sector is projected to show resilience in revenue with a 2.1% increase in 2024, although net profit is expected to decline by 32.5% due to price drops in core products [5] - In Q1 2025, revenue is anticipated to grow by 7.1% and net profit by 81.1%, benefiting from price increases initiated in late 2024 and ongoing demand for functional sugars [5] - The sector may see further price increases for sucralose and potential growth opportunities following the approval of natural sweetener allulose in the domestic market [5]